ClinicalTrials.gg

Program

THDBH120

A development code. Also written as “THDBH120 injection”, “THDBH120 injection (SAD)” and “THDBH120 injection (MAD)”.

Its studies are mostly in Overweight · Diabetes Mellitus, Type 2 · Obesity, led by Tonghua Dongbao Pharmaceutical.

Furthest: phase 2, since Jun 16, 20254 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tonghua Dongbao Pharmaceutical41 open or runningphase 2since Jun 16, 2025Dec 17, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 17, 2024First study: phase 1 study in HealthyFirst studyNCT06744868 · 72 enrolled · China
  2. Apr 23, 2025Phase 1 study in ObesityNCT06951945 · 36 enrolled · China
  3. Jun 5, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT07020949 · 49 enrolled · China
  4. Jun 16, 2025Phase 2 study in OverweightNCT07036601 · 276 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07036601Overweight · China2RecruitingFeb 13, 2026276
NCT07020949Diabetes Mellitus, Type 2 · China1CompletedNov 27, 202449
NCT06951945Obesity · China1CompletedDec 23, 202436
NCT06744868Healthy · China1CompletedSep 22, 202472

How it is read

Names in the registry

  • “THDBH120 injection”, 3 entries
  • “THDBH120 injection (SAD)”, 1 entry
  • “THDBH120 injection (MAD)”, 1 entry

Codes read as this program: THDBH120.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.